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 ABSTRACT 
Background:  When a mechanical ventilator is used, the endotracheal tube can act as a track for 
pathogens to follow into the patient’s lungs where pneumonia can develop.  This project 
evaluates reported Ventilator-Associated Pneumonia (VAP) events at an academic tertiary care 
hospital (TCH) system.   
Objectives:  The objectives of this study are to:  1.)  Identify epidemiological data related to 
VAP, 2.)  Identify the prevalence of possible (ps) and probable (pr) VAP, and 3.)  Compare 
similar hospital groups for factors influencing cases and outcomes. 
Methods:  This project utilized data from the National Healthcare Safety Network (NHSN) and 
the TCH medical record system between January 1, 2013 and August 31, 2014.  Only adult VAP 
patients were included in the study.  Demographic and clinical data were analyzed using SAS 9.3 
software. 
Results:  White men between 50-70 years of age were the majority of persons to develop VAP 
while at the TCH system.  Most patients were diagnosed with psVAP, but had no major 
differences from prVAP patients.  This review shows that daily PEEP values are not being 
monitored by hospitals.  All hospitals had both a high mortality and a high readmission rate.  
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Suburban facilities accounted for 76% of psVAP cases, 41% of mortalities, and 60% of all 
readmissions. 
Conclusions:  Infection Prevention teams, especially in suburban hospitals, must identify the 
cause of high VAP complications and adverse outcomes within the dominant population.  It is 
important that practice and procedure match to ensure patient safety. 
Public Health Significance:  Every community trusts healthcare facilities to provide safe and 
effective treatment.  However, Healthcare-Acquired Infections (HAI) deter individuals from 
optimal health, and may lead to increased antibiotic use and resistance.  Mechanical ventilation, 
while essential, breaches protective barriers and increases the risk for potential HAI.  Infection 
Preventionists aid patients on their journey to better health by working to eliminate HAIs.  This 
study is the first step to aid Infection Prevention teams throughout the healthcare system in 
encouraging continued surveillance, evaluation of practice and procedure, and decreasing 
hospital-acquired infections overall to reinforce community safety. 
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1.0  INTRODUCTION 
Health risks associated with mechanical ventilator use include collapsed lung, lung damage, 
sedative side effects, and infection [1].  An estimated 300,000 patients receive mechanical 
ventilation treatment in the United States each year [2].  Recent studies have shown that 5-10% 
of these ventilated patients develop a Ventilator-Associated Event (VAE) [3].  Another study 
estimated that, on average, VAP patients experience 9.6 additional days of mechanical 
ventilation, 6.1 additional days in the intensive care unit (ICU), and 11.5 additional days in the 
hospital [4].  This is a vicious cycle where individuals who require ventilation are at risk for 
pneumonia and, if infected, are at risk for excess vent days and corresponding costs of treatment.  
However, the life-saving benefits of ventilators outweigh the risk of infection or other side 
effects.   
The probability of developing pneumonia, specifically, increases by one percent each day 
a patient spends on a ventilator system [1].  Longer ventilation creates hazards such as 
readmission and a higher mortality risk [2, 5].  As the number of days the patient is admitted in 
the hospital increases, directly correlated healthcare costs for both the facility and the patient also 
rise [2, 3].  A recent review estimated that, on a per-case basis, Ventilator-Associated Pneumonia 
(VAP) infections resulted in $40,144 extra fees and 13.1 excess days spent in a health-care 
facility [6].  Another study suggests the development of VAP is associated with a mean hospital 
charge to patients of $150,841 [4]. 
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Multiple measures are in place to avoid VAE within hospital ICUs.  Healthcare facilities 
have implemented basic strategies to specifically prevent VAP including:  keeping patient beds 
elevated to between 30 and 45 degrees at all times while on a ventilator, up-keeping patient oral 
care, hand hygiene, and mechanical equipment, and daily assessing the readiness of the patient to 
extubate [7].  Although healthcare guidelines continue to be created and endotracheal tube 
designs have improved, VAP continues to affect patients [8]. 
A major Tertiary Care Hospital (TCH) system comprised of nine hospitals (A-I) 
requested an evaluation of their safety strategies.  Participating hospitals had a total of 100,311 
vent days.  Individual healthcare facilities within the system vary between adult intensive care 
units, specialty care areas, and trauma centers.  Populations served are different due to different 
specialties.  For example, burn patients are usually admitted to hospital C, transplant patients 
taken to hospital E, and so forth.  This is the first evaluation of possible (ps) and probable (pr) 
VAP events within the TCH system.  This quality improvement study was used to determine 
common clinical and demographic characteristics of VAP patients at the TCH system that may 
be related to the infection, identify the prevalence of psVAP and prVAP at the system, and 
complete inter-hospital comparisons of VAP rates. 
A prediction was made that patients of increased age and a social history of alcohol, 
tobacco, or illicit drug use will have a greater chance of developing VAP.  This prediction was 
based on the evidence that behavioral changes and older age affect the immune system.  It is 
likely that psVAP events will be higher than prVAP events.  This is because the prVAP 
definition contains more required variables.  It was also hypothesized that urban and suburban 
hospital locations would not have many differences between patient characteristics, incidence of 
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VAP events, or patient outcomes.  This was based on the fact that all the hospitals included 
follow the same healthcare guidelines for mechanical ventilation safety. 
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2.0  BACKGROUND 
2.1 SURVEILLENCE 
Hospital Acquired Infection (HAI) surveillance is a powerful public health and infection 
prevention tool. One of the major benefits of surveillance is that it gives scientists a base line 
level of infection, and warns of any increase in incidence. The National Healthcare Safety 
Network (NHSN) is an Internet-based surveillance system managed by the Center for Disease 
Control and Prevention (CDC) with a Patient Safety branch to monitor device-associated events 
[8].  VAP is the most frequent device-associated infection in critical-care wards [9].  The NHSN 
is a tool developed for surveillance and plays no part in clinical diagnosis or treatment.  VAP 
surveillance is mandatory in Pennsylvania, but optional in other states.  Increasing the 
surveillance on VAP is crucial to individual hospital and national quality improvement programs 
[5]. 
2.1.1 Infection Prevention 
Infection Prevention teams actively monitor the progress of ventilated patients admitted to the 
healthcare facility they work to keep safe. The teams survey records and laboratory results 
updated by attending physicians and technicians for evidence of an HAI until discharge.  Then, 
they submit reports on the infected patient’s demographic data, HAI type, and pathogens to the 
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NHSN [8].  This quality improvement project takes the information one step further to evaluate 
the compiled data within and between the hospitals in the TCH system.  By identifying risk 
factors, Infection Prevention members could come together to adjust their protocols in order to 
make their infection prevention efforts specifically adjusted for ventilated individuals with 
increased risk factors. 
2.2 VENTILATOR ASSOCIATED PNEUMONIA 
2.2.1 History 
Prior to 2013, VAP was the only ventilator-associated infection that the NHSN monitored.  In 
the past, about 10-20% of patients placed on a ventilator were deemed to have a pneumonia 
condition [3].  Recent research showed that chest radiographs and other clinical symptoms can 
be subjective and inconsistent [2].  For example, patients on a ventilator that developed a fever 
would fit one criteria of the VAP definition.  However, if the patient had a severe underlying 
illness, it cannot be determined if the fever is from a new infection or the previous condition 
[10].  Screening a patient’s daily ventilator settings for lung stability can be used to better predict 
adverse VAE outcomes [5].   
2.2.2 Definition 
In January 2013, the CDC changed their NHSN reporting definition of VAP to make the 
guidelines more objective, structured, and reproducible for all hospital settings [2].  It was 
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created to include quantitative physiological complications known to lead to any type of VAE 
[5].  By creating a broad definition of VAE, surveillance has expanded to include all ventilator-
associated complications, not just pneumonia [3] (for a complete definition, see Appendix A). 
The new algorithm has a nested hierarchy where each rank becomes more specific as 
scaling down the tier: 
1) Ventilator-Associated Condition (VAC), 
2) Infection-related Ventilator-Associated Complication (IVAC), and  
3) Possible and Probable VAP  
Although the definition change was made in an effort to attain more specific 
representation of VAP rates, the new criteria is significantly more complicated.  In simple terms, 
a VAE is identified by the Infection Prevention team using this definition:  deterioration in 
respiratory status after a period of stability or improvement while on a ventilator.   
2.2.3 VAP Timeline 
The day the patient is intubated and mechanical ventilation has begun is considered day one of 
the ventilator period.  After the initial intubation, 2 or more calendar days of stability or 
improvement of lung health ventilation must pass before the patient is considered to potentially 
have a VAE [2].  Following the algorithm, an HAI must first be deemed a Ventilator-Associated 
Condition (VAC) and tracked down the tiers to meet the VAP criteria [11].  Therefore, the 
earliest day on which VAE criteria can be fulfilled is day 3 of mechanical ventilation [2].  The 
actual date of VAE onset in this study is the day 1 (D1) when all criteria for the condition have 
been met.  Clinical data from day 0 (D0), the day before the event, have also been included for 
comparison. 
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The area where the patient was diagnosed with VAE is known as the location of 
attribution.  However, if the D1 occurs on the day of a transfer between locations, the VAP is 
said to be attributed to the new location the patient is transferred to.  A new VAE cannot be 
established until 14 days after D1 [2].  However, if a patient were to be reintubated onto a 
ventilator after stopping ventilation for one full day, an entirely new VAE window period would 
begin. 
The new VAE definition utilizes quantitative measurements of both Positive End-
Expiratory Pressure (PEEP) and Fraction of Inspired Oxygen (FiO2) to monitor lung health [2].  
PEEP can be adjusted on the ventilator as needed to achieve airway pressure greater than 
atmospheric pressure at the end of exhalation.  Following a period of stability, if PEEP or FiO2 
needs to be increased to meet the patient’s needs, there is a possibility of a ventilator 
complication.  Daily PEEP and FiO2 values in this study are defined as the highest value during 
a calendar day that is maintained for at least one hour [2].  PEEP values from 0 to 5 cmH2O are 
considered equivalent. If the PEEP or FiO2 increases ≥ 3 cmH2O or 20% respectively to at least 
8 cmH2O or 50%, the individual is monitored for VAE development. 
2.2.4 Demographic Risk Factors 
Depending on the population, VAP incidence can range between 9% and 27% of patients on 
mechanical ventilation for more than 24 hours [4, 13, 14].  The literature on VAP risk factors 
presents conflicting data.  In a recent retrospective review to assess early risk factors of trauma 
patients who developed late VAP, risk factor analysis demonstrated that age, race, sex, ethanol 
status, and smoker status did not have an impact [14, 15].  However, other investigators have 
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found a risk correlation with certain patient demographics. For instance, one study found chronic 
alcoholism was common among middle-aged patients with VAP [16]. 
There is controversy as to which sex presents more risk for the development of VAP.  
Several studies have identified female sex as a predominant factor in VAP patients [14,16, 17]  
However, others found male sex to be a significant, independent risk factor for the development 
of VAP [4].  In yet another study, sex differences were statistically insignificant [4].  Studies 
showing sex influence include those with and without control groups. 
Some investigators have found that age is associated with VAP, while others did not. 
Studies have shown a wide age range of individuals who develop VAP with a median age around 
65 [14, 18].  However, some studies have found that older age is not a risk factor for VAP [16].  
One study even deemed a significant correlation between younger male patients and VAP events 
[4].   
2.2.5 Clinical Risk Factors 
A number of host factors, clinical factors, and certain ICU locations increase the risk of VAP 
[19].  In a study evaluating a network of nonteaching community hospitals, small hospitals had a 
higher VAP incidence rate than medium or large hospitals despite having lower ventilation rates 
[14].  The evaluation confirmed a relationship between poor outcomes among ventilated patients 
and the inexperience of small hospitals with low bed counts.  In addition, VAP rates at trauma 
ICU can be significantly high and vary among centers [4, 20].  Various trauma patient studies 
have demonstrated that VAP prolongs the duration of mechanical ventilation [15].   
Evidence of infection includes increased patient body temperature above 37.5oC, 
evidence of inflammation including white blood cell (WBC) counts above 3.5-10.5 billion, and 
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laboratory evidence of respiratory infection [2].   Increased patient body temperature has been 
shown to be less frequent among very old patients [16]. An incidence of VAP is considered 
when a patient has secretions, sputum, or positive cultures.  Incidents of psVAP are defined as 
cases when the patient does not necessarily have a positive culture for pathogenic organisms [5].  
Cases of prVAP must meet all of the previous criteria in addition to evidence of positive 
quantitative cultures for pathogenic organisms or respiratory viruses [5]. 
Any and all organism isolated from cultures of lung tissue or pleural fluid could be 
reported as pathogens for psVAP or prVAP.  Patients with viral pneumonia, such as H1N1, are 
often difficult to diagnose with VAP as they may not have typical or significant symptoms [12].  
The most common microorganisms linked with mechanical VAP are:  Staphylococcus aureus, 
Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Enterobacter species 
[4, 5].   VAP can develop within 48 hours of ventilation and risk rises as ventilation increases.  
Pseudomonas aeruginosa, Acinetobacter spp, and Staphylococcus aureus are the most common 
causative agents in late-onset nosocomial pneumonia, and Streptococcus pneumoniae and 
Hemophilus influenzae are more commonly found in early-onset pneumonia [19, 4].  VAP 
patients infected with antibiotic-resistant bacteria or given inappropriate initial antibiotic 
treatment have an increased risk of mortality [4]. 
2.2.6 VAP Patient Outcomes 
One independent risk factor for VAP is the length of mechanical ventilation [4, 16].  Patients 
with VAP have greater number of days in ICU, a longer hospital length of stay, higher costs, and 
higher mortality compared to patients without VAP [4, 18]. 
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ICU mortality rates of 24% to 76% have been reported for VAP [10, 13].  VAP patients 
can have a 2 to 10-fold higher risk of death compared to ventilated, VAP-negative patients.  
Death rates have been associated with the severity of the infecting pathogen [10, 16].  Sixty 
percent of elderly patients, 85 years of age and older, placed on a ventilator after acute lung 
injury will spend their last days in the hospital [2, 16]. 
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3.0  METHODS 
3.1 STUDY OBJECTIVES 
The purpose of this study is to identify demographic characteristics of patients at the TCH 
system associated with the development of VAP infection.  Additional aims include detecting the 
prevalence of psVAP and prVAP at the TCH system, and make comparisons between urban and 
suburban hospital groups within the TCH system for related factors. 
3.2 STUDY DESIGN 
To address these objectives, a systematic retrospective review was designed to include all 
reported VAP events and corresponding patient details to the NHSN from the academic TCH 
system between January 1, 2013, and August 1, 2014. 
3.3 STUDY AREA 
The chosen TCH system is a large network of hospitals (A-I) in Western Pennsylvania which 
includes acute care hospitals, long term acute care hospitals, and inpatient rehabilitation 
 11 
facilities.  The healthcare facilities B, C, E, and F are all located within a 2 mile radius of each 
other.  These hospitals were grouped together as urban locations with patients of similar 
demographics and social standings.  All other surrounding healthcare facilities (A, D, and G) 
were classified as suburban. 
3.4 STUDY POPULATION 
3.4.1 Inclusion Criteria 
Adult patients at least 18 years old and deemed by Infection Prevention teams to have been 
infected with VAP while admitted to the TCH system sometime between January 1, 2013 and 
August 31, 2014 were included in this study.  There were a total of 190 patients detected with 
VAP between the chosen date range.  Patients on Airway Pressure Release Ventilation are 
included in the study, but only changes in FiO2 were monitored [2].  Patients being weaned from 
a ventilator are also included in the study because they spent at least a portion of a day on a 
ventilator where contamination was possible [2].  One patient was recorded twice for more than 
one VAP event per admission as per reporting criteria [5]. 
3.4.2 Exclusion Criteria 
Patients who may have been clinically diagnosed with pneumonia, but did not meet the criteria 
for the NHSN definition were excluded from the study.  Patients on high frequency ventilation or 
extracorporeal life support are also excluded from VAE surveillance [2].  Ventilated children and 
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neonates were excluded as the VAE algorithm used is only applicable to adult mechanically 
ventilated patients [2]. 
3.5 DATA COLLECTION 
Clinical as well as demographic risk factor information were extracted and organized from the 
NHSN surveillance data already being collected.  In addition, the TCH medical record system, 
Cerner, was utilized via PowerChart and Theradoc.  Patient information, clinician history and 
physical examination notes, social history, patient vital reports, laboratory and microbiology 
database, and discharge and death summaries were utilized to obtain pertinent data not included 
in NHSN reports.  All collected information was organized into one Excel data extraction form. 
3.5.1 NHSN Data Collection 
Upon request, a summary of NHSN data for all VAP patients was provided by a UPMC System 
level data analyst.  The analyst then matched the NHSN material to patient medical record data 
and highlighted any inconsistencies.  The summary delivered to me included:  the hospital the 
patient was admitted to, age, sex, race, length of stay in the hospital, length of stay in an ICU, 
number of days patient was on a ventilator, VAP type, pathogens reported in association with 
diagnosis, and second and third HAI diagnosis.  It is important to note that the ICU type listed is 
not necessarily the location of VAP attribution.   
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3.5.2 Cerner Data Collection 
This study used the electronic health records of adult patients to identify criteria that may have 
contributed to the VAP.  Electronic patient medical records included reports of abuse or even 
slight use of illicit drugs, tobacco, or alcohol upon hospital admission were considered in this 
analysis.  Previous histories of use were not considered.  Reports from family members were 
considered if patients were not able to communicate social histories themselves.  Demographic 
data collected incorporated admission dates and hospital summaries of discharge or death 
reports.  The hospital length of stay and vent day data for certain patients had to be verified by 
the number of bed days and number of ventilator setting data recorded respectively. 
Laboratory information included vital reports of body temperature, WBC counts, daily 
ventilator settings and culture results from the hospital’s microbiology database.  The cultures of 
blood, pleural fluid, sputum, and urine samples often grew multiple organisms.  For this study, 
only the pathogen with the heaviest growth counts were included.  Charts were also consulted for 
any missing information from NHSN reports. 
3.6 DATA ANALYSIS 
By using the clinical evidence that Infection Prevention teams have collected and reported to 
NHSN, an insight into each patient’s VAP experience was revealed.  The patterns and 
distribution of those with the highest risk of infection were examined through frequency 
distributions using SAS 9.3 software.  Fischer’s Exact tests were used to analyze this descriptive 
information per hospital locations. 
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4.0  ETHICS 
Approval for this study was provided by the Total Quality Council/Quality Improvement Review 
Committee for the TCH system.  All medical record numbers, and patient and hospital names 
were removed from this analysis to preserve patient confidentiality in accordance with HIPAA 
policy. 
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5.0  RESULTS 
5.1 OVERALL DATA 
5.1.1 Patient Demographics 
Altogether, 159 of the 190 VAP patients were included in the analysis.  A total of 31 patients 
including 2 hospitals (H & I) were excluded from analysis:  15 patients from one hospital (H) 
due to the inability of the UPMC System level data analyst to match the patient details, and 16 
other patients from several hospitals – including the only patient from hospital I – due to 
incomplete data to confirm VAP infection or data suggested the patient did not fit the criteria for 
VAP. 
As shown in Table 1, out of the 159 patients included in this study, 120 (75.5%) were 
male.  Seven patients were not willing to report their race, and a social history was not available 
for every patient due to their mental status during admission, unavailable records, or attending 
physicians failing to report the history.  Out of 152 patients willing to report their race, 133 
(87.5%) reported being Caucasion while only 19 (12.5%) were African American.  The median 
age was 58 with a range of 19 to 85 years (Table 1).  A total of 85 (53.5%) individuals were 
within the age range of 50 to 70 years of age.  Only 24 patients were between 71 and 90 years of 
age.  Out of 133 patients, 36.8% reported current use of tobacco or smoking upon admission.  
 16 
Out of 127 patients, a little less than half (48.0%) reported current use of alcohol upon 
admission.  Out of 104 patients, 13.5% reported illicit drug use. 
 
Table 1. Demographic Characteristics of All VAP Patients in the TCH System 
Variable Total (n=159) 
Male sex 120 (75.5%) 
Age 50-70 (53.5% 
*Race: - 
White 133 (87.5%) 
African American 19 (12.5%) 
*Social history: - 
Alcohol 61 (48.0%) 
Tobacco 49 (36.8%) 
Illicit drugs 14 (13.5%) 
* Race n=152, Social history:  Alcohol n=127, Tobacco n=133, Illicit drugs n=104  
There urban hospitals (B, C, E, and F) had a VAP incidence rate of 1.8 per 1,000 vent 
days within the study period.  There were a total of 142 (89.3%) VAP patients admitted to urban 
hospitals.  All other suburban hospitals (A, D, and G) had a VAP incidence rate of .84 per 1,000 
vent days.   Suburban locations contained 17 (10.7%) of the VAP patients.  The number of 
patients attributed to each specific hospital can be found in Table 2.  Hospital E has a large bed 
count of 720 where 69.2% of the total VAP patients were admitted.  Hospitals B and G each held 
only 1 patient diagnosed with VAP. 
 
 17 
Table 2. Percentage of VAP Patients Admitted to Urban and Suburban Hospitals 
Hospital 
Code 
Bed 
Count 
Location Incidence Rate (per 
1,000 vent days) 
Total 
Patients Percent 
A 446 Suburban 0.77 9 5.7% 
B 310 Urban 0.58 1 0.6% 
C 488 Urban 0.72 9 5.7% 
D 424 Suburban 1.2 7 4.4% 
E 720 Urban 2.2 110 69.2% 
F 520 Urban 1.4 22 13.8% 
G 249 Suburban 0.41 1 0.6% 
Urban 2038 4 1.8 142 89.3% 
Suburban 1119 3 .84 17 10.7% 
 
5.1.2 Clinical Characteristics 
Patients were admitted to their respective ICU locations with 15 (9.4%) to the 
medical/surgical, 38 (23.9%) to trauma, 41 (25.8%) to medical, and 65 (40.9%) to the surgical 
ICU.  The ICU location of the patient is not necessarily the location of intubation or attribution 
of VAP. 
Table 3 displays the urban and suburb ICU subtype differences.  In suburban locations 
specifically, medical/surgical and trauma ICU patients had equivalent (3.8%) VAP events with 
surgical ICU only representing 1.3% of cases. 39.6% of all VAP events were due to patients in 
urban hospitals placed in surgical ICU.  In suburban hospitals, medical/surgical and trauma ICU 
locations accounted for 35.3% of all the 17 VAP events. 
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Table 3. Frequency of VAP Events per ICU Type in Urban and Suburban Hospitals 
ICU Type Suburb Urban Total 
Medical/Surgical 6 (35.3%) 9 (6.3%) 15 (9.4%) 
Medical 3 (17.7%) 38 (26.8%) 41 (25.8%) 
Surgical 2 (11.8%) 63 (44.4%) 65 (40.9%) 
Trauma 6 (3.8%) 32 (20.1%) 38 (23.9%) 
Total 17 (10.7%) 142 (89.3%) 159 (100.0%) 
 
The lowest, median, and highest measurements of clinical variables affecting VAP 
patients are listed in Table 4 for D1.  In comparison, measurements for D0 are also included in 
the table.  Patient body temperature before and during VAP events ranged from 33.9oC to 
41.3oC.  PEEP was only recorded for 55 of the 159 patients on D1.  However, FiO2 values were 
recorded for every patient both on D0 and D1.  WBC counts varied considerably between 
patients.  The only statistically significant increase from D0 to D1 was WBC counts (t-test 
p=0.032). 
 
Table 4. Range of Clinical Characteristics of VAP Patients in the TCH System 
TEMP, body temperature. D0, day before the event. D1, date of VAP onset. FiO2, Fraction of 
Inspired Oxygen. PEEP, Positive End-Expiratory Pressure. WBC, white blood cell.  
 
Variable N Variable Reported Minimum Median Maximum 
Temp (oC) D0 159 33.9 38.0 40.7 
Temp (oC) D1 159 36.0 38.0 41.3 
FiO2 (%) D0 159 30.0 70.0 100.0 
FiO2 (%) D1 159 40.0 70.0 100.0 
PEEP (cmH2O) D0 67 5.0 15.0 44.0 
PEEP (cmH2O) D1 55 5.0 15.0 46.0 
WBC D0 155 2.0 11.4 52.5 
WBC D1 158 1.4 12.5 41.0 
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The most frequent VAP pathogens reported to the NHSN were Staphylococcus aureus 
(23.27%), Pseudomonas aeruginosa (8.81%), Escherichia coli (8.18%), and Enterobactor 
aerogenus (5.66%).  However, there was a large variety of additionally reported microorganisms 
throughout all VAP patients. 
5.1.3 Patient Outcomes 
The median length of stay in each ICU was 21 days with a wide range of 1 to 242 days.  
Similarly, the median length of stay at the hospital was 24 days with a range of 6 to 142 days.  
The median duration of mechanical ventilation was 18 days with a minimum of 6 and a 
maximum of 186 days.  Maximum ICU and vent days are greater than the total length of stay due 
to the fact that total days in the hospital could not be recorded for two of the VAP patients as 
they were still admitted to the hospital upon data collection.  These patients could potentially 
have more ICU or vent days that are not included this analysis.   
 A total of 50 patients developed at least one additional HAI during the same 
hospital stay as incurring the VAP infection (Table 5).  Of the additional HAI events, 41 had a 
second event while 9 even had a third.  The most common additional HAI other than VAP was a 
urinary tract infection affecting 24 (48.0%) patients, followed by surgical site infections at 8 
(16.0%), and gastrointestinal infection at 7 (14.0%) events.  This data does not reflect concurrent 
general infections also at the time of VAP events.   
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Table 5. Distribution of Additional HAI Events in TCH System 
HAI Type Total (n=50) 
Second HAI 41 
Third HAI 9 
Bloodstream Infection 5 (10.0%) 
Eye, Ear, Nose and Throat 1 (2.0%) 
Gastrointestinal 7 (14.0%) 
Pneumonia 3 (6.0%) 
Skin and Soft Tissue 2 (4.0%) 
Surgical Site Infection 8 (16.0%) 
Urinary Tract Infection 24 (48.0%) 
 
Excluding the two patients not yet discharged, 59 (37.6%) of the patients succumbed to 
their health complications during hospital admission.  Of the 100 safely discharged, 55 (56.1%) 
patients were readmitted: 47 (85.5%) within 1-30 days, 5 (9.1%) within 31-60 days, and 3 (5.5%) 
within 61-90 days.  Of the 55 patients readmitted within 90 days, only 2 died. 
5.2 POSSIBLE AND PROBABLE VAP 
5.2.1 Incidence Rate 
A little more than half of the patients, 57.9%, were diagnosed with psVAP while the other 42.1% 
were deemed prVAP events (Table 6).  Urban locations contained 85.9% of all psVAP infections 
and 94.0% of the total prVAP events.  Thirteen of the 17 total suburban VAP patients (76.5%) 
were psVAP cases. 
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Table 6. Percent of psVAP and prVAP per Suburban and Urban VAP Patients 
Variable Suburban Urban Total 
psVAP 13 (76.5%) 79 (55.6%) 92 (57.9%) 
prVAP 4 (23.5%) 63 (44.4%) 67 (42.1%) 
 
5.2.2 Clinical Characteristics 
Table 7 lists the clinical variables, other than pathogens, that may have been indicative of VAP 
type.  There is no statistically significant difference in WBC or FiO2 from D0 to D1 but change 
in temp was different between the groups (p=0.036).  All PEEP values were within the range of 5 
to 46 cmH2O. 
Table 7. Clinical Variables Affecting psVAP and prVAP Events 
TEMP, body temperature. D0, day before the event. D1, date of VAP onset. FiO2, Fraction of 
Inspired Oxygen. PEEP, Positive End-Expiratory Pressure. WBC, white blood cell.  
VAP 
Type 
Total 
Patients Variable 
N Variable 
Reported Minimum Median Maximum 
psVAP 
 
92 Temp (oC) D0 
Temp (oC) D1 
FiO2 (%) D0 
FiO2 (%) D1 
PEEP (cmH2O) D0 
PEEP (cmH2O) D1 
WBC D0 
WBC D1 
92 
92 
92 
92 
32 
28 
88 
91 
35.9 
36.1 
30.0 
40.0 
5.0 
5.0 
2.0 
1.4 
38.2 
37.9 
60.0 
70.0 
23.5 
18.0 
10.6 
11.5 
40.6 
41.3 
100.0 
100.0 
41.0 
46.0 
34.5 
34.9 
prVAP 67 Temp (oC) D0 
Temp (oC) D1 
FiO2 (%) D0 
FiO2 (%) D1 
PEEP (cmH2O) D0 
PEEP (cmH2O) D1 
WBC D0 
WBC D1 
67 
67 
67 
67 
35 
27 
67 
67 
33.9 
36.0 
40.0 
40.0 
5.0 
5.0 
3.6 
2.6 
37.9 
38.1 
80.0 
80.0 
10.0 
15.0 
12.9 
14.2 
40.7 
41.3 
100.0 
100.0 
44.0 
45.0 
52.5 
41.0 
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5.2.3 Patient Outcomes 
The median duration of mechanical ventilation for psVAP was 17 days with a wide range of 6 to 
123 days (Table 8).  Similarly, the median vent days for prVAP was 21 with a range of 6 to 186 
days.  One patient developed VAP after only 1 day spent in the ICU.  Total ICU days and length 
of stay were not available for the two prVAP patients not yet discharged from their respect 
hospitals. 
Table 8. Duration of Patient Hospital Stay per psVAP and prVAP Events 
 
5.3 VAP BY URBAN AND SUBURBAN LOCATIONS 
5.3.1 Clinical Characteristics 
Table 9 shows the specific indicators, other than pathogens, of VAP that may be affecting 
specific urban or suburban locations.  There were no statistically significant differences between 
variables from D0 to D1 in either suburban or urban groups.  PEEP was only recorded for 4 of 
the 17 suburban VAP patients and less than half of urban patients on both D0 and D1.  The 
VAP 
Type 
Total 
Patients Variable 
N Variable 
Reported Minimum Median Maximum 
psVAP 
 
92 Vent Days 
ICU Days 
Total Length of Stay 
92 
92 
92 
6.0 
1.0 
6.0 
17.0 
19.0 
23.5 
123.0 
131.0 
142.0 
prVAP 67 Vent Days 
ICU Days 
Total Length of Stay 
67 
65 
65 
6.0 
2.0 
6.0 
21.0 
25.0 
31.0 
186.0 
242.0 
106.0 
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median FiO2 values for VAP patients on D1 in suburban hospitals was 80% and only 70% in 
urban locations.   
 
Table 9. Clinical Variables Involved with VAP at Suburban and Urban Hospitals 
Location Total Variable N Minimum Median Maximum 
Suburb 17 Temp (oC) D0 
Temp (oC) D1 
FiO2 (%) D0 
FiO2 (%) D1 
PEEP (cmH2O) D0 
PEEP (cmH2O) D1 
WBC D0 
WBC D1 
17 
17 
17 
17 
4 
4 
17 
17 
36.4 
36.3 
30.0 
50.0 
5.0 
5.0 
3.3 
3.4 
37.6 
38.0 
100.0 
80.0 
23.0 
28.5 
12.1 
13.6 
39.3 
41.3 
100.0 
100.0 
41.0 
46.0 
52.5 
41.0 
Urban 142 Temp (oC) D0 
Temp (oC) D1 
FiO2 (%) D0 
FiO2 (%) D1 
PEEP (cmH2O) D0 
PEEP (cmH2O) D1 
WBC D0 
WBC D1 
142 
142 
142 
142 
63 
51 
138 
141 
33.9 
36.0 
40.0 
40.0 
5.0 
5.0 
2.0 
1.4 
38.0 
38.0 
70.0 
70.0 
12.0 
15.0 
11.3 
12.4 
40.7 
41.3 
100.0 
100.0 
44.0 
45.0 
34.5 
35.5 
TEMP, body temperature. D0, day before the event. D1, date of VAP onset. FiO2, Fraction of 
Inspired Oxygen. PEEP, Positive End-Expiratory Pressure. WBC, white blood cell.  
 
The most common VAP pathogens associated within urban locations were 
Staphylococcus aureus (19.5%), Pseudomonas aeruginosa (6.9%), and Escherichia coli (7.6%).  
While the suburban hospitals had similar pathogens to protect against, β-hemolytic Streptococci 
(1.9%) caused more infections than Escherichia coli (0.6%).  There were three viral H1N1 cases 
which were all associated with urban hospitalization.  Again, there were a large variety of 
pathogens associated with VAP between suburban and urban hospitals. 
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5.3.2 Patient Outcomes 
Table 10 shows both suburban and urban locations kept patients on a ventilator for a median of 
18 days.  The maximum duration of ventilation for suburban hospitals was 50 days while at least 
one patient in an urban hospital had 186 vent days.  Median ICU days and total length of hospital 
stay for urban patients was slightly higher than suburban, but maximum days in urban locations 
(242 and 142 respectively) greatly outnumbered the maximum of suburban hospitals (46 and 50 
days). 
Table 10. Range of Days VAP Patients Spent in Suburban and Urban Hospitals 
Location Total Variable N Minimum Median Maximum 
Suburb 17 Vent Days 
ICU Days 
Total Length of Stay 
17 
17 
17 
9.0 
10.0 
10.0 
18.0 
19.0 
22.0 
50.0 
46.0 
50.0 
Urban 142 Vent Days 
ICU Days 
Total Length of Stay 
142 
140 
140 
6.0 
1.0 
6.0 
18.0 
22.0 
25.5 
186.0 
242.0 
142.0 
 
A total of 52 (88.1%) of the 59 patient deaths upon initial admission occurred within urban 
hospitals.  Of suburban patients, 41.2% died on initial admission, and 60.0% were readmitted 
within 90 days.  Only 37.14% of the 142 urban patients passed away, and 49 (55.7%) were 
readmitted after initial discharge. 
 
Table 11. VAP Patient Outcomes in Suburban and Urban Hospitals 
Outcome Suburban Urban Total (n=157) 
Mortality 7 (41.2%) 52 (37.1%) 59 
Readmission 6 (60.0%) 49 (55.7%) 55 
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Of the additional HAI infections, 47 occurred in urban locations.  Within Hospital F 
alone, 6 of the 22 patients had one additional HAI while 2 others had three total HAI events.  All 
of the suburban additional HAIs in Hospital A.  The only two HAI events occurring in addition 
to VAP in suburban locations were bloodstream and urinary tract infections.  The most common 
HAI, accounting for 41.03% of the total second HAI events, at urban TCHs was urinary tract 
infections, as shown in Table 12. 
 
Table 12. Percent of Additional HAI Events per Suburban and Urban VAP Patients 
HAI Suburban Urban 
Second HAI 2 39 
Third HAI 1 8 
Bloodstream Infection 2 (66.7%) 3 (6.4%) 
Eye, Ear, Nose and Throat 0 1 (2.1%) 
Gastrointestinal 0 7 (14.9%) 
Pneumonia 0 3 (6.4%) 
Skin and Soft Tissue 0 2 (4.3%) 
Surgical Site Infection 0 8 (17.0%) 
Urinary Tract Infection 1 (33.3%) 23 (48.9%) 
Total 3 47 
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6.0  DISCUSSION 
While the literature does not provide a definitive list of risk factors, this analysis shows a clear 
relationship between VAP events and certain patient demographics.  This study demonstrates 
that white males are the majority of patients who develop VAP infection while on a mechanical 
ventilator within this TCH system.  Patients of this background within the age range of 50 to 70 
made up over half of the study population.  There seemed to be no association between recent 
patient social history and VAP incidence. 
This study shows that patient social history of tobacco or drug use may not be associated 
with pneumonia development while on a ventilator.  However, alcohol use may have an 
influence.  Previous research has shown a discrepancy between the correlation of VAP 
development and social history [14, 15].  While some studies have shown no correlation, others 
have found a high ethanol status in certain VAP patients [16].   
It has been 1.5 years since the implementation of the latest VAP definition which has 
increased the objectivity of HAI diagnosis by adding quantitative PEEP and FiO2 values to 
criteria [2].  These results indicate that patient vital signs are indeed subjective, and consistent 
ventilator setting data should be recorded.  However, in this study PEEP values were only 
recorded for 55 of the 159 VAP events.  PEEP and FiO2 values, while similar, are the only 
quantifiable components directly associated with lung health.   
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In accordance with criteria, it only takes a short amount of ventilation time, in this case 6 
days, to become infected with VAP.  The results were also consistent with previous reports that 
VAP infections caused longer ventilation time, ICU days, and total days admitted to the hospital 
[4, 16, 18].  The length of stay in each ICU, on a ventilator, and in a hospital consisted of a wide 
range between 1 and 242 days.  Initial overall mortality and readmission rates of VAP patients 
was high, but readmission mortality was low.  Overall mortality counts were similar to 
previously published data from teaching hospitals [10, 13]. 
As predicted, cases of psVAP were more common than prVAP in both urban and 
suburban locations.  Between VAP types, both showed a wide range of total days spent in the 
healthcare facility including ICU and vent days.  Individuals with prVAP had a higher median 
length of vent days, ICU days, and total stay in the healthcare facility.  Patients with prVAP also 
had an increased WBC count on D1 compared to psVAP.  These results suggest that there is a 
difference between psVAP and prVAP, and that prVAP may be more severe. 
For suburban hospitals, trauma and med/surgical ICU wards were tied for highest number 
of VAP cases.  Consistent with the overall data, surgical ICUs had the highest association with 
VAP events in the urban hospital group.  Over half of the VAP infections, no matter the ICU 
ward location, were caused in urban hospitals.  The most common microbial pathogens affecting 
VAP patients within this TCH system are consistent with published data [4, 5].  The most 
common pathogens found in this TCH system were Staphylococcus aureus, Pseudomonas 
aeruginosa, Escherichia coli, and Enterobactor aerogenus.  The most frequent pathogens 
associated with VAP did not differ between locations.   
The VAP patients from this TCH system suffered a large number of additional HAIs.  
These infections should especially be monitored in surgical ICU wards.  Of the additional HAI 
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events, the most common incident was a urinary tract infection.  It cannot be determined if the 
additional infections aided in VAP development.  However, additional HAI events, especially 
urinary tract infections, need to be significantly reduced.   
Although there were no significant demographic differences of patients admitted between 
urban or suburban hospital, VAP outcomes were affected by the size and experience of hospitals.  
Patients admitted to suburban locations had a higher mortality and readmission rate than urban 
VAP patients.  However, there was no significant difference in duration of mechanical 
ventilation, and each location had more psVAP than prVAP.   
6.1 STRENGTHS AND LIMITATIONS 
The strengths of this study include the use of a national database with sequential information 
specific to VAP events, and the ability to match the data with existing medical records.  This 
study gives a base line of modifiable variables to prevent VAP events, and warns of outcome 
risks should these events continue.  The database used provides many more variables to 
potentially study in the future including underlying health conditions, infections upon admission, 
and antibiotic use before admission.  Ongoing surveillance also allows for a similar data review 
in the future to identify any trends. 
All included patients were located within a similar region of western PA, and were all 
from the same hospital system under one protocol to prevent VAP.  The sample size was still 
large after the elimination of unmatched patients.  The results were consistent with what previous 
studies have reported. 
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Limitations of this study include the retrospective nature of the data collection.  Reporting of 
valid data was only as efficient as the patient’s clinicians to record data.  Therefore, missing data 
from the variables this study considered was to be expected.  We can assume, because the data 
was collected from one TCH system, that there are little differences between the hospitals in 
terms of mechanical ventilation methods, weaning strategies, or laboratory protocols [5].  
However, the results may not be generalizable to community hospitals. 
The analysis of patient demographics was limited by the large number of missing social 
history data for the patients included in the analysis.  In addition, there were suggestions of 
reporting bias as patients questioned multiple times for a social history during the same 
admission period resulted in varying answers.  Furthermore, since the patients included in this 
study may have had multiple health conditions, it is impossible to say with certainty that specific 
symptoms or mortality were caused by VAP alone.   
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7.0  CONCLUSION 
Despite its limitations, this study succeeded in providing baseline data of VAP epidemiology in 
the TCH system.  VAP incidence greatly affects patient safety and health.  Effective strategies 
for preventing VAP and other HAI events must be implemented.   
Surprisingly, white males of middle age are at greatest risk of developing VAP infection 
while on a mechanical ventilator within this TCH system.  It is not clear why this demographic 
characteristic is so prevalent among infected patients.  By using this information to prevent 
psVAP and prVAP cases, this TCH system could use special techniques to increase ventilated 
patient safety overall.  Future studies should include a comparison group of matched ventilated 
but pneumonia negative patients to prove that patient characteristics are specifically associated 
with VAP infection or merely mechanical ventilation. 
This review shows that daily PEEP values are not being monitored by most hospitals.  In 
many cases, only FiO2 ventilator settings were recorded for each mechanically ventilated patient.  
This difference in protocol vs. practice reduces the neutrality of the diagnosis by causing 
Infection Prevention teams to rely solely on FiO2 values and arbitrary symptoms.  Utilizing all 
standardized care processes and regularly monitoring each patient’s progress is vital for 
prevention [3].  It is important that practice and procedure match when recording ventilated 
patient data.  Both PEEP and FiO2 should be monitored in order to ensure that VAP cases are 
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acknowledged at the earliest possible date.  Furthermore, monitoring ready values for any 
decrease in lung health could prompt early demands for sputum cultures. 
It is important that procedures be developed to protect against additional HAI events, 
especially urinary tract infections.  Cultures of potential infection should especially be monitored 
in surgical ICU wards.  Hospitals of smaller size and with less experience at safe ventilation 
protocols, evidently require further education and guidance.  Suburban hospitals should be 
closely monitored in order to decrease VAP incidence, mortality, and readmission rates. 
The findings of this quality improvement project help distinguish common patient 
characteristics which local hospitals could adjust for in the future.  In addition to the current 
basic quality improvement strategies, it would be interesting to utilize a specialized oral care 
approach for individuals with a higher risk of developing VAP such as during and after surgery.  
The use of oral health care techniques has been moderately shown to decrease the amount of 
VAP [3].  This project hopefully will encourage the TCH system to continue studies that 
evaluate how current ventilation practices could be improved.   
 The lifesaving benefits of mechanical ventilation for thousands of American citizens have 
been fraught with frequent VAP and other HAI events, resulting in excess admission days and 
costs of treatment.  With the population continually living longer and the need for ventilation 
potentially increasing, surveillance tools must continually be used to monitor VAP events, and 
Infection Prevention teams must constantly evaluate protocol to provide a safe environment for 
ventilated patients as a public health priority.   
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2.) Increase in daily 
minimum* PEEP values of ≥ 3 
cmH2O over the daily minimum 
PEEP in the baseline period†, 
APPENDIX: 2013 NHSN VENTILATOR ASSOCIATED EVENT DEFINITIONS
Ventilator-Associated Condition (VAC): [21] 
Patient has a baseline period of stability or improvement on the ventilator, defined by ≥ 2 
calendar days of stable or decreasing daily minimum* FiO2 or PEEP values. The baseline period 
is defined as the two calendar days immediately preceding the first day of increased daily 
minimum PEEP or FiO2. 
and 
After a period of stability or improvement on the ventilator, the patient has at least ONE of the 
following indicators of worsening oxygenation: 
or 
*Daily minimum defined by lowest value of FiO2 or PEEP during a calendar day that is
maintained for at least 1 hour. 
†Daily minimum PEEP values of 0-5 cmH2O are considered equivalent for the purposes of VAE 
surveillance.
1.) Increase in daily 
minimum* FiO2 of ≥ 0.20 (20 points) 
over the daily minimum FiO2 in the 
baseline period, sustained for ≥ 2 
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Infection-related Ventilator-Associated Complication (IVAC): 
Patient meets criteria for VAC 
and 
on or after calendar day 3 of mechanical ventilation and within 2 calendar days before or after 
the onset of worsening oxygenation, the patient meets both of the following criteria: 
1.) Temperature > 38 °C or < 36°C, OR white blood cell count ≥ 12,000 cells/mm3 or ≤ 4,000 
cells/mm3. 
and 
2.) A new antimicrobial agent(s)* is started, and is continued for ≥ 4 calendar days. 
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2.) Positive culture (qualitative, 
semi-quantitative or quantitative) of 
sputum*, endotracheal aspirate*, 
bronchoalveolar lavage*, lung tissue, or 
protected specimen brushing* 
  *Excludes normal 
respiratory/oral flora, mixed respiratory/oral 
flora or equivalent, Candida species or yeast 
not otherwise specified, Coagulase-negative 
Staphylococcus species, Enterococcus 
species 
 
 
Possible Ventilator-Associated Pneumonia (psVAP): 
Patient meets criteria for VAC and IVAC 
and 
on or after calendar day 3 of mechanical ventilation and within 2 calendar days before or after 
the onset of worsening oxygenation, one of the following criteria is met: 
 
or 
 
 
1.) Purulent respiratory 
secretions (from one or more 
specimen collections):  defined as 
secretions from the lungs, bronchi, or 
trachea that contains > 25 neutrophils 
and < 10 squamous epithelial cells per 
low power field [lpf, x100] 
• See additional instructions for 
using the purulent respiratory 
secretions criterion in the VAE 
Protocol.  
 
 35 
Probable Ventilator-Associated Pneumonia (prVAP): 
Patient meets criteria for VAC and IVAC 
and 
on or after calendar day 3 of mechanical ventilation and within 2 calendar days before or after 
the onset of worsening oxygenation, ONE of the following criteria is met: 
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2.) ONE of the following (without 
requirement for purulent respiratory 
secretions):  
• Positive pleural fluid culture 
(where specimen was obtained during 
thoracentesis or initial placement of chest 
tube and NOT from an indwelling chest 
tube)  
• Positive lung histopathology  
• Positive diagnostic test for 
Legionella spp.  
• Positive diagnostic test on 
respiratory secretions for influenza virus, 
respiratory syncytial virus, adenovirus, 
parainfluenza virus, rhinovirus, human 
metapneumovirus, coronavirus 
 
or 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. 
1.) Purulent respiratory 
secretions (from one or more 
specimen collections—defined as for 
possible VAP)  
and  
ONE of the following:  
• Positive culture of 
endotracheal aspirate*, ≥ 105 CFU/ml 
or equivalent semi-quantitative result  
• Positive culture of 
bronchoalveolar lavage*, ≥ 104 
CFU/ml or equivalent semi-
quantitative result  
• Positive culture of lung 
tissue, ≥ 104 CFU/g or equivalent 
semi-quantitative result  
• Positive culture of protected 
specimen brush*, ≥ 103 CFU/ml or 
equivalent semi-quantitative result  
*Same organism exclusions as 
noted for Possible VAP.  
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